Abstracts tagged "Vasculitis"

Abstract Number: 1546 • ACR Convergence 2023
Eosinophilic Granulomatosis with Polyangiitis: Clinical Suspicion Red Flags Identification by a Systematic Literature Review and Multidisciplinary Expert Consensus
Ricardo Blanco¹, Iñigo Rúa-Figueroa², Roser Solans³, Maria C Cid⁴, Marina Blanco⁵, Ismael Garcia Moguel⁶, Francisco Perez Grimaldi⁷, Ana Noblejas⁸, Moises Labrador³, Cristian Domingo⁹, Georgina espigol¹⁰, Fernando Sanchez Toril¹¹, Francisco Ortiz-Sanjuán¹², Ebymar Arismendi¹³ and Jose María Alvaro-Gracias¹⁴, ¹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ²Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ³Internal Medicine Department, H. Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain, ⁴Hospital Clinic Barcelona, Barcelona, Spain, ⁵Pneumology Department, Hospital Universitario de A Coruña, Madrid, Spain, ⁶Allergy Department, Hospital Universitario 12 de Octubre, Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain, ⁷Pneumology Department, H. University of Jerez, Cádiz, Spain, ⁸Internal Medicine Department, Hospital Universitario La Paz, Madrid, Spain, ⁹Pneumology Department, Corporació Sanitaria Parc Taulí, Universitat Autònoma de Barcelona, Barcelona, Spain, ¹⁰Autoimmune Diseases Department, Hospital Clínic, FCRB-IDIBAPS, Universitat de Barcelona, Barcelona, Spain, ¹¹Pneumology Department, Hospital Arnau Vilanova, Valencia, Spain;, Valencia, Spain, ¹²Hospital Universitario y Politécnico La Fe, Valencia, Spain, ¹³Pneumology Department, Hospital Clínic de Barcelona, Barcelona, Spain, Universitat de Barcelona, Spain and CIBERES, Barcelona, Spain, ¹⁴Hospital General Universitario Gregorio Marañon, Madrid, Spain
Background/Purpose: Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare ANCA-associated vasculitis, characterized histologically by eosinophilic tissue infiltration, necrotizing vasculitis, and eosinophil-rich granulomatous inflammation. The diagnosis…
Abstract Number: 1650 • ACR Convergence 2023
Optic Nerve Sheath Measurement as a Disease Activity Biomarker in Giant Cell Arteritis
Carolyn Ross¹, Stephanie Ducharme-Benard², Samer Hussein³, Rosalie-Selene Meunier³, Christian Pagnoux⁴ and Jean-Paul Makhzoum¹, ¹Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ²Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ³Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁴Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Recently, optic nerve sheath (ONS) enhancement using contrast-enhanced magnetic resonance imaging of the brain and orbits was observed in most patients with biopsy-proven GCA.…
Abstract Number: 2396 • ACR Convergence 2023
Diagnostic Performance of a Newly-Launched Canadian Fast-Track Ultrasound Clinic Performed by Rheumatologists for Diagnosis of Giant Cell Arteritis
Jean-Charles Mourot¹, Sai Yan Yuen², Mihaela Popescu³ and Nicolas Richard⁴, ¹Université de Montréal, Mont-Royal, QC, Canada, ²Maisonneuve-Rosemont Hospital, Mont-Royal, QC, Canada, ³Maisonneuve Rosemont Hospital, Longueuil, QC, Canada, ⁴Hopital Maisonneuve Rosemont, Montreal, QC, Canada
Background/Purpose: Giant Cell Arteritis (GCA) poses diagnostic challenges for clinicians as there is no universal gold standard. We hypothesize that launching a Fast-Track Ultrasound (US)…
Abstract Number: 2419 • ACR Convergence 2023
Visual Manifestations in Giant Cell Arteritis: Identification of Risk Factors from the ARTESER Registry
Juan Molina-Collada¹, Marta Domínguez², Rafael Benito Melero-Gonzalez³, Elisa Fernandez-Fernandez⁴, Maria. T Silva-Diaz⁵, Joaquín M. Belzunegui⁶, Ismael González⁷, Julio Sanchez Martin⁸, Javier Narvaez⁹, Eva Galíndez¹⁰, javier Mendizábal¹¹, Leticia Leon Mateos¹², Javier Loricera⁸, Alejandro Muñoz¹³, Santos Castañeda¹⁴, Iván Castellvi¹⁵, Marina Tortosa-Cabañas¹⁶, Vanesa Navarro¹⁷, Carlos Galisteo¹⁸, Ivette Casafont-Solé¹⁹, Jose Andres Roman Ivorra²⁰, TAREK CARLOS SALMAN MONTE²¹, Margarida Rocha²², Carlota Laura Iñiguez²³, Maria Vanesa Hernandez Hernandez²⁴, Cristina Campos²⁵, María Alcalde²⁶, Antonio Juan Mas²⁷, Francisco Javier Prado²⁸ and Ricardo Blanco²⁹, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³CHU Vigo, O Carballino, Spain, ⁴La Paz University Hospital, Madrid, Spain, ⁵Complexo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁶Hospital Universitario Donostia, Donostia, Spain, ⁷Hospital Universitario de León, León, Spain, ⁸Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁹Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁰Hospital Universitario de Basurto, Bilbao, Spain, ¹¹Complejo Hospitalario de Navarra, Pamplona, Spain, ¹²IDISSC Hospital Clinico San Carlos, Madrid, Spain, ¹³Hospital universitario Virgen del Rocío, El Viso de Alcor, Spain, ¹⁴Hospital Universitario de la Princesa, Madrid, Spain, ¹⁵Hospital de Santa Creu i Sant Pau, Barcelona, Spain, ¹⁶Ramon y Cajal University Hospital, Madrid, Spain, ¹⁷H Moisès Broggi, Sant Joan Despí, Barcelona, Spain, ¹⁸Hospital Universitario Parc Taulí, Barcelona, Spain, ¹⁹Hospital Germans Trias i Pujol, Badalona, Spain, ²⁰Hospital Universitari i Politècnic la Fe, Valencia, Spain, ²¹Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ²²Osakidetza, Bilbo, Spain, ²³Hospital Universitario Lucus Augusti, Lugo, Spain, ²⁴Hospital Universitario de Canarias, La Laguna, Spain, ²⁵Rheumatology Unit, Hospital General Universitario de Valencia, Valencia, Spain, ²⁶Hospital Severo Ochoa, Madrid, Spain, ²⁷Hospital Universitario Son Llàtzer, Mallorca, Spain, ²⁸Research department Hospital Infantil de México Federico Gómez, Mexico City, Mexico, ²⁹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Visual loss is one of the most feared complications in giant cell arteritis (GCA). Some factors have been previously associated with visual loss, as…
Abstract Number: 2603 • ACR Convergence 2023
Impact of IL-6 Receptor Small Nucleotide Polymorphism Asp358Ala on T Cell Activity and Clinical Outcomes in Patients with Giant Cell Arteritis
Christopher Redmond¹, Robert Zorc², McKella Sylvester³, Cameron Rankin⁴, Rebecca Kuan⁵, Kristina Wells⁶, Lily Dai⁷, Kaitlin Quinn⁸, Massimo Gadina⁹ and Peter Grayson¹⁰, ¹National Institutes of Health, Hagerstown, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases/National Institutes of Health, Bethesda, MD, ³Colgate University, Bethesda, MD, ⁴NIAMS, NIH, Washington, DC, ⁵NIH, Bethesda, MD, ⁶University of California Davis, Bethesda, MD, ⁷NIH, Germantown, MD, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁹National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ¹⁰National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD
Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis in adults that commonly involves the aorta and branching arteries, resulting in multiple symptoms including…
Abstract Number: 0272 • ACR Convergence 2023
Risk Factors for Severe Outcome in Susac Syndrome: A National Cohort Study
Marion Peyre¹, Arthur Mageau¹, Marie-cecile Henry Feugeas², Serge Doan², Caroline Halimi², Isabelle Klein³, Tiphaine Goulenok², Chrystelle Francois², Marie-Paule Chauveheid², Thomas Papo¹ and Karim Sacre¹, ¹Université Paris Cité, Paris, France, ²Assistance Publique Hopitaux de Paris, Paris, France, ³Clinique Alleray-Labrouste, Paris, France
Background/Purpose: Susac syndrome (SuS) is a rare vasculitis affecting the brain, retina and inner ear in young women. Nonreversible hearing loss is the main long-term…
Abstract Number: 0702 • ACR Convergence 2023
Large Vessel Vasculitis Increases Risk of Acute Myocardial Infarction in Patients Admitted for Congestive Heart Failure : A Nationwide Inpatient Database Study
Yanint Raksadawan, Sabahat Usmani, Harigopal Sandhyavenu, Thatiana Schulze Goni, Jalpan Patel, Hafiz Muhammad Waqar Younas and Amro Taha, Weiss Memorial Hospital, Chicago, IL
Background/Purpose: Cardiac disease has been known to be a major morbidity and mortality cause in vasculitis. Large vessel vasculitis is mostly associated with pericarditis, myocarditis…
Abstract Number: 0855 • ACR Convergence 2023
Real-world Experience with Avacopan in ANCA Vasculitis: A Multi-center Retrospective Cohort Analysis
Sebastian Sattui¹, Colin Diffie², Aisha Shaikh³, Julia Ford⁴, David Bulbin⁵, Ora Gewurz-Singer⁶, Faten Aqeel⁷, Reza Zonozi⁸, Abdallah Sassine Geara⁹, Dustin Le⁷, Gabriel Sauvage⁸, Madeline Chung¹⁰, Isabelle Ayoub¹⁰, Frank Cortazar¹¹, Andrew Bomback¹², Karina Guaman¹², Jason George¹³, John Niles⁸ and Duvuru Geetha⁷, ¹University of Pittsburgh, Pittsburgh, PA, ²Washington University, St. Louis, MO, ³Washington University in St. Louis, St. Louis, MO, ⁴University of Michigan, Ann Arbor, MI, ⁵Geisinger Health System, Danville, PA, ⁶University of Michigan, Huntington Woods, MI, ⁷Johns Hopkins University, Baltimore, MD, ⁸Massachusetts General Hospital, Boston, MA, ⁹University of Pennsylvania, Philadelphia, PA, ¹⁰Ohio State University, Columbus, OH, ¹¹New York Nephrology, Watervliet, NY, ¹²Columbia University, New York, NY, ¹³Geisenger Health, Danville, PA
Background/Purpose: Avacopan (AVP) is a recently approved adjunct therapy for remission induction of ANCA-associated vasculitis (AAV). Data on real-world use of AVP in AAV are…
Abstract Number: 1551 • ACR Convergence 2023
Measurement of Sinonasal Disease Activity in Granulomatosis with Polyangiitis
Roger Yang¹, Ellen Romich², Shubhasree Banerjee³, Naomi Amudala³, Peter Merkel³, Joshua Baker³ and Rennie Rhee³, ¹University of Pennsylvania, Montréal, QC, Canada, ²Hospital of the University of Pennsylvania, Media, PA, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: In granulomatosis with polyangiitis (GPA), sinonasal inflammation can be severe and significantly impact quality of life. Little is known about the most effective local…
Abstract Number: 1871 • ACR Convergence 2023
Utility of Infrared Thermography in Patients with Digital Gangrene
Nidhish Chandra M, Puneet Kumar, Urmila Dhakad, Shweta Bhardwaj, Sanjay Pruthviraj Buddha, Parag Vijayvergia and Lily Singh, King George Medical University, Lucknow, India
Background/Purpose: Digital gangrene has been described as a complication of several Autoimmune Inflammatory Rheumatic Diseases(AIIRD). Due to multiple underlying mechanisms causing digital gangrene in AIIRD…
Abstract Number: 2397 • ACR Convergence 2023
Impact of Exposure to Environmental Air Pollution on the Onset of Giant Cell Arteritis
Milena Bond¹, Alessandro Tomelleri², Maria Antonietta Reatini³, Corrado Campochiaro⁴, Giorgio Cattani³, Lorenzo Dagna⁵, Maurizio Rossini⁶, Christian Dejaco⁷ and Giovanni Adami⁶, ¹Azienda sanitaria dell'Alto Adige, Merano, Italy, ²Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milano, Italy, ³Italian Institute for Environmental Protection and Research, Rome, Italy, ⁴IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, ⁵Department of Internal Medicine, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy, ⁶Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy, ⁷Department of Rheumatology, Medical University Graz, Graz, Austria; Department of Rheumatology, Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsius Medical University, Brunico, Italy
Background/Purpose: Environmental air pollution (AP) has been found to affect vascular inflammation and to contribute to the risk of onset and flare of autoimmune diseases1,2.…
Abstract Number: 2420 • ACR Convergence 2023
Sex Differences in Giant Cell Arteritis: Data from the ARTESER Registry
Delia Fernández-Lozano¹, Marta Domínguez², Javier Narvaez³, Noemi Garrido-Puñal⁴, Eugenio De Miguel⁵, Paula V. Estrada-Alarcón⁶, Iñigo Hernández-Rodríguez⁷, Maria. T Silva-Diaz⁸, Joaquín M. Belzunegui⁹, Clara Moriano Morales¹⁰, Julio Sanchez Martin¹¹, Itziar Calvo-Zorrilla¹², Vicente Aldasoro¹³, lydia Abasolo¹⁴, Javier Loricera¹¹, Patricia Moya¹⁵, Maria J. García-Villanueva¹⁶, Carles Galisteo¹⁷, Anne Riveros-Frutos¹⁸, Francisco Ortiz-Sanjuán¹⁹, Selene Labrada-Arrabal²⁰, Margarida Rocha²¹, Carlos García-Porrúa²², Maria García-González²³, Clara Molina Almela²⁴, María Alcalde²⁵, Antonio Juan Mas²⁶, Fernando Alonso²⁷, Santos Castañeda²⁸, Ricardo Blanco²⁹ and on behalf of the Collaborative Group members³⁰, ¹Hospital de Mérida, Merida, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Hospital Universitario Virgen del Rocío, Sevilla, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ⁷Hospital do Meixoeiro. Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁸Complexo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁹Hospital Universitario Donostia, Donostia, Spain, ¹⁰Rheumatology, Hospital Universitario de León, León, Spain, ¹¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹²Basurto University Hospital, Bilbao, Spain, ¹³Hospital Universitario de Navarra, Pamplona, Spain, ¹⁴Hospital Clínico San Carlos, Madrid, Spain, ¹⁵Hospital de Santa Creu i Sant Pau, Barcelona, Spain, ¹⁶Hospital Ramón y Cajal, Madrid, Spain, ¹⁷Hospital Universitario Parc Taulí, Sabadell, Spain, ¹⁸Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, ¹⁹Hospital Universitario y Politécnico La Fe, Valencia, Spain, ²⁰Hospital del Mar, Barcelona, Spain, ²¹Osakidetza, Bilbo, Spain, ²²Hospital Universitario Lucus Augusti, Lugo, Spain, ²³Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ²⁴Hospital General de Valencia, Valencia, Spain, ²⁵Hospital Severo Ochoa, Madrid, Spain, ²⁶Hospital Universitario Son Llàtzer, Mallorca, Spain, ²⁷Spanish Society of Rheumatology, Madrid, Spain, ²⁸Hospital Universitario de la Princesa, Madrid, Spain, ²⁹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³⁰ARTESER group, Madrid, Spain
Background/Purpose: Giant cell arteritis (GCA) is the most common vasculitis in North America and Western Europe. GCA is more likely to occur in women (1).…
Abstract Number: 2604 • ACR Convergence 2023
Premature Vascular Smooth Muscle Cells Senescence Driven by Interleukin-6-Mitochondrial STAT3-Mitofusin 2 Signaling in Takayasu’s Arteritis
Chenglong Fang¹, Lihong Du¹, Lili Li², Yuexin Chen³, Zuoguan Chen⁴, Yongjun Li⁴, Jing Li¹, Mengtao Li⁵, xiaofeng Zeng⁶ and Xinping Tian⁵, ¹Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, ²The State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and School of Basic Medicine, Peking Union Medical College, Beijing, China, ³Department of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, ⁴Department of Vascular Surgery, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China, ⁵Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁶Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: Takayasu’s arteritis (TAK) is characterized by persistent vascular inflammation involving aorta and its main branches, which is an important prosenescent factor that in turn…
Abstract Number: 0291 • ACR Convergence 2023
Myopathy Related to Small-to-medium-sized Vessel Vasculitis: Immunopathological Characteristics
Shun Nomura, Yasuhiro Shimojima, Takanori Ichikawa, Daigo Miyazaki, Dai Kishida and Yoshiki Sekijima, Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan
Background/Purpose: Muscular involvement develops as the initial manifestation of small-sized vessel vasculitis (SV) and medium-sized vessel vasculitis (MV).The musculoskeletal lesion has been found as a…
Abstract Number: 0703 • ACR Convergence 2023
Cardiovascular Disease-Related Mortality in Primary Systemic Vasculitis
Alicia Rodriguez-Pla, Sierra Pacific Arthritis and Rheumatology Centers, Fresno, CA
Background/Purpose: Cardiovascular disease (CVD) is the leading cause of death in patients with the most common subtypes of primary systemic vasculitides. We aimed to estimate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].